Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 220-410-5 | CAS number: 2756-56-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The NOAEL of Isobornyl propionate is >=270 mg/kg bw based on read across from a sub-chronic study carried out with Isobornyl acetate (similar to OECD 408) and supported with information from a sub-chronic study with Cyclacet.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: read-across from a (similar to) guideline study
- Justification for type of information:
- The repeated dose toxicity is based on information from Isobornyl acetate. The read across rationale is presented in the Repeated dose Endpoint summary. The accompanying files are also attached there.
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 270 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- histopathology: non-neoplastic
- organ weights and organ / body weight ratios
- Remarks on result:
- other: Result obtained from read-across substance Isobornyl acetate (CAS 125-12-2). No correction for the difference in molecular weight is applied as a conservative approach.
- Dose descriptor:
- NOAEL
- Remarks:
- renal effects (rat specific)
- Effect level:
- 15 mg/kg bw/day (actual dose received)
- Based on:
- test mat. (total fraction)
- Sex:
- male/female
- Basis for effect level:
- histopathology: non-neoplastic
- organ weights and organ / body weight ratios
- urinalysis
- water consumption and compound intake
- Remarks on result:
- other: Result obtained from read-across substance Isobornyl acetate (CAS 125-12-2). No correction for the difference in molecular weight is applied as a conservative approach.
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 504.6 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: No toxicological significant effects observed, except hydrocarbon nephropathy which was not considered in the NOAEL derivation for human health, being a rat specific phenomenon.
- Remarks on result:
- other: Result obtained from read-across substance Cyclacet (EC 911-396-0). No correction for the difference in molecular weight is applied as a conservative approach.
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 90 mg/kg bw/day (actual dose received)
- System:
- hepatobiliary
- Organ:
- liver
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- no
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 90 mg/kg bw/day (actual dose received)
- System:
- urinary
- Organ:
- kidney
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- no
- Conclusions:
- For Isobornyl propionate the NOAEL is considered to be the highest dose tested at 270 mg/kg bw at which some rat specific effects in liver and kidney were observed. This value is used as the NOAEL as it is below 1000 mg/kg bw, the limit dose.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 270 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
No studies are available on the substance itself. The information is derived from a sub-chronic study on the close structural analogue Isobornyl acetate. In this study a NOAEL of 270 mg/kg bw was derived (the highest dose tested). The liver effects (slight hypertrophy and sligth biliary effects) were not considered adverse. The hydrocarbon nephropathy is a male rat specific phenomena. The absence of adverse effects is supported with information from Cyclacet, which was tested in a sub-chronic study in which similar non-adverse effects were seen up to 1500 mg/kg bw. In the absence of human-relevant effects the NOAEL for systemic toxicity is established at 270 mg/kg bw/day.
Sub-chronic study with Isobornyl acetate (similar to OECD 408)
In the sub-chronic oral toxicity study, similar to OECD 408, 15 male and female CFE rats were exposed daily to 0 (vehicle control), 15, 90 and 270 mg/kg bw/day by oral gavage for a period of 13 weeks (Gaunt 1971). 5 additional animals/ sex were exposed for 2 to 6 weeks for the 0, 90 and 270 mg/kg bw /day dose groups. Corn oil was used as vehicle. The body weight of the animals and their intake of food and water were measured weekly.
Urine was collected for urinalysis from all rats during the final week of treatment and, additionally, during wk 6 from five rats of each sex of each group of the main study. After receiving their final dose, the animals were fasted for 24 hr and then killed by an overdose of barbiturate. Blood was collected from the aorta for haematological examination and serum analyses. Gross pathology and histopathology/ measurement of organ weights was performed.
No deaths and no abnormalities in behaviour or appearance occurred during the study.
There were no significant differences between test and control animals in the rate of bodyweight gain. No treatment related haematological effects or alterations in serum parameters were observed. Urinalysis revealed increased cell excretion in rats receiving 270 mg/kg/day and at wk 13 this effect was seen also in animals receiving 90 mg/kg/day. The males given 270 mg/kg/day also showed an impairment of urine-concentrating ability. At wk 6 this was seen only after prolonged (16-20 hr) water deprivation but at wk 13 it was also seen after dehydration for 6 hr. Although the absolute kidney weight was increased only in females at wk 13, the kidney weight expressed relative to body weight was increased at wk 6 in males and at wk 13 in both sexes. The relative liver weight was increased in both sexes of rats given 270 mg/kg/day for 13 wk. Both absolute and relative caecal weights were increased at wk 13 at the highest level of treatment. No abnormalities were seen at autopsy but the histological examination revealed focal tubular degeneration and atrophy in the kidneys in the high dose group and, in males only, a vacuolation of the tubular epithelium. Slight vacuolation of the epithelial cells of the intrahepatic bile ducts was also seen in males but not considered adverse. Based on these results a NOAEL of 270 mg/kg bw/day was derived in the absence of human-relevant adverse effects.
Supporting study with Cyclacet (according to OECD 408)
In a sub-chronic repeated dose toxicity study performed according to OECD 408 and under GLP conditions, rats were orally exposed for 90 days via the food (Harlan 2012). The dose levels were 0, 200, 2000, 6000, and 20000 ppm, corresponding to 0, 15.3, 154.9, 464.1, and 1504.6 mg/kg bw/day, respectively. Clinical signs, functional observations, body weight change, dietary intake, and water consumption were monitored during the study. During week 7 and at the end of the study, haematology, blood chemistry and urinalysis were evaluated. Furthermore, oestrus cycle assessment was performed on female animals between week 6 and 7 and week 12 and 13.Opthalmoscopic examination was performed at the start and end of the study in control and high-dose animals. At the end of the study, all animals were subjected to gross necropsy examination and histopathological examination of tissues was performed on animals from control and high-dose. Furthermore, sperm assessment was performed on males at necropsy. Reduced overall body weight was observed in male and female animals in the highest dose group, correlated with reduced food consumption and adverse effects on food efficiency, indicating decreased food palatability. At the highest dose level, reduced chloride concentration, sodium concentration, aspartate aminotransferase levels, alanine aminotransferase levels, bile acid levels, and increased cholesterol levels were observed in male animals. The observed changes in aminotransferases, bile acid and cholesterol can be explained by the reduced food consumption. Changes in chloride and sodium concentrations may be explained by the observed kidney effects in males. Increased kidney weights were also observed in males, as well as hyalin droplet nephropathy, which is a rat-specific effect that is not relevant for humans. In females, no toxicologically significant effects were observed in clinical chemistry, organ weights or histopathology. Therefore the NOAEL could be established as the highest dose tested, 20000 ppm or 1500 mg/kg bw/day, under the conditions of this test.
Repeated dose toxicity of Isobornyl propionate (Cas no. 2756-56-1using read across from Isobornyl acetate (125-12-2) and Cyclacet (Generic Cas no. 54830-99-8)
Introduction and hypothesis for the analogue approach
Isobornyl propionate consists of an exo-1,7,7-Trimethylbicyclo[2.2.1]heptane) structure to which a propionic ester is attached. For this substance no repeated dose toxicity information is available. In accordance with Article 13 of REACH, lacking information should be generated whenever possible by means other than vertebrate animal tests, i.e. applying alternative methods such as in vitro tests, QSARs, grouping and read-across. The analogue approach is selected since for the structurally related analogues Isobornyl acetate and Cyclacet reliable repeated dose toxicity information is available that can be used for read across. Cyclacet is added to support that all parameters assessed in an OECDTG 408 up to the current standard also no effects are seen.
Hypothesis: Isobornyl propionate has the same repeated dose toxicity as Isobornyl acetate and Cyclacet.
Available information: For Isobornyl acetateand Cyclacet sub-chronic toxicity studies are available. For Isobornyl acetate a published study similar to OECD TG 408 is available (Rel. 2). In this study a human relevant NOAEL is derived of 270 mg/kg bw. For Cyclacet a sub-chronic study is performed according to OECD TG 408, in which a human relevant NOAEL of >=1500 mg/kg bw was derived. In both studies alpha-hydrocarbon nephropathy was seen, which is specifically for male rats and not relevant for humans.
Target chemical and source chemical(s)
Chemical structures of the target chemical and the source chemical(s) are shown in the data matrix, including relevant physico-chemical properties.
Purity / Impurities
Isobornyl propionate is a mono-constituent >=88%, with impurities similar to the parent substance and < 10%.
Analogue approach justification
According to REACH Annex XI 1.5 read-across can be used to replace testing when the similarity can be based on a common backbone and a common functional group. When using read-across the result derived should be applicable for C&L and/or risk assessment and it should be presented with adequate and reliable documentation, which is presented below.
Analogue selection:For Isobornyl propionate the one methyl shorter Isobornyl acetate was selected as an analogue being the closest analogue for which repeated dose toxicity information is available. E.g. for Isobornyl butyrate no such information was found on the ECHA site or in the RIFM database. Cyclacet is added as an analogue to support the findings in Isobornyl acetate study and show that parameters requested in current guidelines and not tested in the older study can be covered with the Cyclacet test results.
Structural similarities and differences:Isobornyl propionate and Isobornyl acetate have the same backbone and functional ester group. The only difference between the two is the propionate and acetate group, respectively, which will result in a higher molecular weight of the first one.
Isobornyl propionate is also very similar to Cyclacet. These substances have a very similar hydrocarbon backbone and the same functional ester group. The double bond in Cyclacet backbone is not near the ester bond and will not present additional electrophilicity and thus reactivity. The propionate versus the acetate will not affect the electrophilicity of the substance or its metabolites.
Toxico-kinetic, Absorptionvia all routes will be similar in view of similar appearance, molecular weights and physico-chemical parameters.Metabolism:Isobornyl propionate, Isobornyl acetate and Cyclacet will hydrolyse to a similar extent based on the close pKa’s of both propyl and ethyl acid: 4.88 and 4.54, respectively. In addition the ester will be cleaved by carboxyl esters to a similar extent: the ester bond is not hindered to any extent. This is also true for Cyclacet: the acetic ester will be easily cleaved. After the ester cleavage the substance and its analogues are all three secondary alcohols. These alcohols will be conjugated and excreted via the kidneys (EFSA, 2008). There is also a metabolic pathway that will bind the alcohol to alpha-2u globulins and as such transported to the kidneys, where the alcohols are excreted and the alpha-2u globulins sediment when overloaded. Propyl and ethyl (acetic) acid are normal body constituents and are metabolised in the Krebs cycle.
Toxico-dynamic aspects: Isobornyl propionate and its related esters demand significant metabolism in the liver resulting in increased liver weights, which is seen in all repeated dose studies. This is considered adaptive in absence of functional liver changes. The transport of the metabolites with alpha-2u globulins results in sedimentation of the alpha-2u globulin in the male rat kidneys when the sedimentation is higher than the removal rate. This results in alpha-hydrocarbon nephropathy in the male rat and is not considered relevant for humans. Overall Isobornyl propionate will not present adverse effects similar to other similar esters which hydrolyse into secondary alcohols such as Isobornyl acetate and Cyclacet.
Uncertainty of the prediction:There are no remaining uncertainties other than those addressed above.
Data matrix
The relevant information on physico-chemical properties and toxicological characteristics are presented in the data matrix.
Conclusions on hazard and risk assessment
For Isobornyl propionate no repeated dose toxicity information is available. Information from two analogues can be used for read across. When using read across the result should be applicable for classification and labelling and risk assessment as well as presented with reliable and adequate documentation. This documentation is presented in the current document. Isobornyl acetate does not show adverse effects in a sub-chronic study up to 270 mg/kg bw (OECD TG 408), which is supported with the Cyclacet study in which a NOAEL >=1500 mg/kg bw was found to show that for all current OECD TG 408 parameters also no effects are seen. For conservative reasons the NOAEL of Isobornyl acetate will be used to derive a NOAEL of 270 mg/kg bw
Final conclusion: Isobornyl propionate has a sub-chronic NOAEL of 270 mg/kg bw.
Data matrix to support the read across to Isobornyl propionate from Isobornyl acetate and Cyclacet on repeated dose toxicity
Common names |
Isobornyl propionate |
Isobornyl acetate |
Cyclacet |
Chemical structures |
|||
|
Target |
Source |
Source |
CAS no. |
2756-56-1 |
125-12-2 |
2500-83-6 (5-yl) and 54830-99-8 (generic) |
EINECS |
220-410-5 |
204-727-6 |
911-369-0 |
REACH registration |
2018 |
Registered |
Registered |
Empirical formula |
C13H22O2 |
C12H20O2 |
C12H16O2 |
Molecular weight |
210.32 |
196.29 |
192.25 |
Phys-chem properties |
|
|
|
Physical state |
Liquid |
Liquid |
Liquid |
Log Kow (measured) |
5.0 (IFF measured) |
4.3 (Simonich EpiSuite) |
3.9 (IFF measured) |
Human health |
|
|
|
Acute Toxicity Oral LD50 mg/kg bw |
5000 (OECD TG 401) |
10000 (OECD TG 401) |
2750 (OECD TG 401) |
Sub-chronic Repeated dose toxicity mg/kg bw |
270 (Read across) |
270 (OECD TG 408) |
>=1500 (OECD TG 408) |
References
EFSA, Flavouring Group Evaluation 87, (FGE.87)1, Consideration of bicyclic secondary alcohols, ketones and related esters evaluated by JECFA (63rd meeting) structurally related to bicyclic
secondary alcohols, ketones and related esters evaluated by EFSA in FGE.47 (2008)
Scientific Opinion of the Panel on Food Additives,Flavourings, Processing Aids and Materials in Contact with Food, site visited May, 2018;
http://www.efsa.europa.eu/sites/default/files/scientific_output/files/main_documents/746.pdf
Justification for classification or non-classification
Based on the available data the substance does not need to be classified according to EU CLP (EC No. 1272/2008 and its amendments).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.